

First Three Years of the Congenital Adrenal Hyperplasia Neonatal Screening Program of the State of Paraná, Southern Brazil

GABRIELA KRAEMER^{1,2}, SUZANA NESI-FRANÇA¹, LUIZ DE LACERDA¹, MARCELLA LIMA², JULIENNE CARVALHO¹, MOUSELINE DOMINGOS², IVY FURTADO², ROSANA PEREIRA¹ ¹UFPR, Brazil ²FEPE, Brazil

Poster Number: P2-P203

No conflicts of interest

INTRODUCTION

- Diagnosis of Congenital Adrenal Hyperplasia (CAH) is a challenge for the pediatrician due to the complexity of its pathophysiology and the variety of its clinical manifestations.
- Female newborns (NB) with classical forms of CAH present virilization of the external genitalia while in boys it is usually normal.
- Salt-losing form, if not treated, develops acute adrenal insufficiency and death in the first weeks of life.
- Neonatal Screening for CAH (CAH-NS) of the State of Paraná commenced in 2013.

AIMS

- To evaluate the prevalence of CAH in the State of Paraná
- To characterize interfering factors in the prevalence of false positive (FP) tests in CAH-NS
- To determine sensitivity, specificity, accuracy, positive and negative predictive values and FP rate of the employed 17-OHP method.

RESULTS

- Prevalence of the classical form of CAH in the state of Paraná was 1:21,596 live births, with higher incidence in the west and southwest regions of the state.
- Female: male ratio: 1.4:1.0.
- Prematurity and neonatal stress were related to false positive screening values.
- 17-OHP method in blood spot sample sensitivity: 100%; specificity and accuracy: 99.9%; predictive positive value: 5.1%; predictive negative value: 100%; recall rate: 0.99% and false positive rate: 0.08%.

Figure 1. Diagram of the study population




Figure 2. 17 OHP blood spot values according to age at collection






Figure 3. Prevalence of CAH in Brazil and Paraná



References

- PORTAL DA SAÚDE. NASCIDOS VIVOS - PARANÁ .
- <http://www.tabnet.sesa.pr.gov.br/tabnetsesa/dh?sistema/sinasc99diante/nascido>
- WHITE, P. C. Nat Rev Endocrinol, v. 5, n. 9, p. 490-8, Sep 2009
- FEPE, Fundação Ecumênica de Proteção ao Excepcional
- HAYASHI, G. et al. Arq Bras Endocrinol Metabol, v. 55, n. 8, p. 632-7, 2011
- PEZZUTI, I. L. et al. J Pediatr (Rio J), v. 90, n. 3, p. 300-7, 2014
- NASCIMENTO, M. L. et al. Arq Bras Endocrinol Metabol, v. 58, n. 7, p. 765-71, 2014
- KOPACEK, C. et al. BMC Pediatr, v. 17, n. 1, p. 22, Jan 17 2017

Figure 4. Trend of blood spot 17 OHP values in each patient



CONCLUSIONS

- Challenges of CAH screening program: to minimize errors in the collection of the blood spots; standardization of the method of serum 17OHP determination and, to afford adequate treatment to all affected children.
- Clinical evaluation is fundamental for proper diagnose in order to avoid overtreatment.

